An Anti-Cancer Drug Candidate OSI-027 and its Analog as Inhibitors of mTOR: Computational Insights Into the...

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• The mammalian target of rapamycin (mTOR) is a key regulator of cell growth and metabolism, implicated in cancer.
• OSI-027 is a selective, orally bioavailable inhibitor of mTOR with demonstrated anti-cancer activity.
• Understanding the molecular interactions of OSI-027 with mTOR is crucial for drug development.

Purpose of the Study:

• To investigate the binding mode and molecular interactions of OSI-027 with mTOR using computational approaches.
• To identify key residues involved in the binding of OSI-027 to mTOR.
• To discover novel OSI-027 analogs with improved inhibitory potential against mTOR.

Main Methods:

• Molecular docking simulations were employed to predict the binding pose of OSI-027 within the mTOR active site.
• Molecular dynamics (un)binding simulations were performed to analyze the stability and dynamics of the OSI-027-mTOR complex.
• Virtual screening of OSI-027 analogs was conducted to identify potential superior inhibitors.

Main Results:

• The study elucidated the specific interactions between OSI-027 and mTOR, highlighting important residues both within and outside the catalytic site.
• Molecular dynamics simulations provided insights into the dynamic binding process and identified critical residues for sustained inhibition.
• Virtual screening identified an OSI-027 analog (CID: 73294902) as a more potent inhibitor than OSI-027 and the native ligand PI-103.
• The proposed analog shares the catalytic site but exhibits a distinct (un)binding pathway compared to OSI-027.

Conclusions:

• Computational analyses provide valuable insights into the mechanism of OSI-027-mediated mTOR inhibition.
• The identified OSI-027 analog represents a promising candidate for further investigation as an anti-cancer therapeutic.
• This study offers a foundation for the rational design of novel mTOR inhibitors.